

Regenerative aesthetics: The role of stem cells and growth factors in skin rejuvenation

Sara Umar

Aesthetic Medicine Intern, Lahore, Pakistan.

Abstract

Regenerative aesthetics is an emerging paradigm that prioritizes tissue repair and biological rejuvenation over temporary correction of age-related change.¹ Stem-cell-based approaches, especially adipose-derived mesenchymal stem cells (ADSCs), can stimulate fibroblast activity, enhance collagen synthesis and support angiogenesis, contributing to improved dermal quality and scar remodeling.^{2,3} In parallel, growth-factor strategies, e.g. fibroblast or MSC-derived growth-factor formulations and platelet-rich plasma (PRP) have shown clinically meaningful improvements in photoaging and acne scars, particularly when paired with procedures like microneedling or lasers.^{4,5} Early human data also suggest that topical platelet-derived exosomes can reduce cellular senescence markers and up-regulate extracellular-matrix pathways in aged skin.⁶ However, translation is limited by variability in preparation protocols, lack of standardization and evolving regulatory guidance for human cell/tissue-based products and exosome-containing products.^{7,8} This review summarizes current evidence for stem cells, PRP/ growth factors and exosomes in aesthetic practice and highlights future directions for standardized, evidence-based use.⁹

Keyword: Regenerative aesthetics; Stem cells; Growth factors; PRP; Skin rejuvenation.

Received: September 02, 2025 | **Accepted:** October 08, 2025 | **Published:** January 06, 2026

Citation: Umar S. Regenerative aesthetics: The role of stem cells and growth factors in skin rejuvenation. *Pak J Med Surg Aesthet.* 2025;1(3):101-110.

Introduction

Skin aging is driven by interacting intrinsic (chronological, genetic) and extrinsic (UV, pollution, lifestyle) factors that together produce recognizable phenotypes and functional decline.^{10,11} At the tissue level, chronic UV and oxidative stress up-regulate matrix metalloproteinases (MMPs), fragment dermal collagen, and create a stiff, degraded extracellular-matrix (ECM) microenvironment that further impairs fibroblast function and collagen homeostasis.^{12,13}

Traditional aesthetic interventions (neuromodulators, fillers, energy devices) improve appearance but largely act at the level of phenotype rather than addressing upstream biological drivers.¹⁴

By contrast, regenerative aesthetics seeks to restore cellular signaling and matrix architecture. Contemporary approaches harness MSCs/ ADSCs, paracrine growth factors/ conditioned media, and extracellular vesicles (exosomes) to stimulate fibroblast activity, collagen/elastin production, angiogenesis and wound repair.¹⁵⁻¹⁷ Clinically, ADSC-conditioned media and ADSC-derived products have been investigated for photoaging, atrophic scars, hair disorders, and wound healing;¹⁶ growth-factor topical formulations have demonstrated improvements in facial wrinkling in randomized split-face trials;¹⁸ and

Address or corresponding

Dr. Sara Umar, BDS
Aesthetic Medicine Intern,
Lahore, Pakistan
Phone: +923234252146
Email: saraumar96@outlook.com

early translational studies indicate that topical platelet-exosome preparations can reduce dermal senescence signaling and favor ECM remodeling in photo-damaged skin.¹⁹

As these biologically active therapies move into practice, clinicians must align with standardization and regulatory frameworks (e.g. minimal manipulation and homologous use for HCT/PS; evolving oversight of exosome products) to ensure safety, reproducibility and durable outcomes.²⁰

Mechanisms of Action

Regenerative aesthetic therapies aim to harness the body's own healing processes to repair and rejuvenate tissues. Stem cell therapy (especially using mesenchymal stem cells, MSCs) contributes to skin regeneration via two key mechanisms: the cells can differentiate into various tissue cells and, importantly, secrete a rich "secretome" of growth factors and extracellular vesicles that drive repair. Adipose-derived stem cells (from fat) exemplify this dual action; they enhance collagen synthesis, promote fibroblast proliferation, and reduce oxidative stress in aging skin, which in turn improves skin elasticity and texture through paracrine signaling (often mediated by exosomes). In a similar paracrine fashion, exosomes (nano-sized extracellular vesicles released by stem cells and other cells) and growth factors act as messengers between cells, modulating the local environment to favor regeneration. They facilitate intercellular communication, dampen excessive inflammation, and accelerate tissue remodeling. For example, human MSC-derived exosomes have been shown to enhance wound healing, reduce inflammation, and stimulate fibroblast proliferation in the skin, illustrating how cell-free components can mimic the benefits of live cell therapy.²¹

Platelet-rich plasma (PRP) is another cornerstone of regenerative medicine with direct relevance to aesthetics. PRP is derived from the patient's own blood and contains a high concentration of platelets which

degranulate to release a cocktail of growth factors (e.g. PDGF, TGF- β , VEGF, EGF, bFGF) and adhesion proteins. Upon intradermal injection, these bioactive factors trigger the classical wound-healing cascade and collagen remodeling. In essence, PRP jump-starts tissue repair by initiating hemostasis, promoting new extracellular matrix deposition, angiogenesis, and stimulating proliferation of dermal cells. The net effect is increased collagen and elastin production and improved dermal architecture over time. Though the precise mechanism in skin rejuvenation is still being elucidated, the growth factors in PRP clearly induce dermal fibroblasts to lay down new collagen and other matrix components, leading to tighter, thicker skin and improved texture.²²

Microneedling-assisted delivery (also known as percutaneous collagen induction therapy) provides a synergistic mechanism of action. The act of microneedling creates microscopic punctures in the epidermis and superficial dermis, which by itself stimulates a controlled wound-healing response characterized by release of growth factors and new collagen/elastin production. This neocollagenesis helps improve skin firmness and reduces fine lines or scars. Moreover, the micro-channels created in the stratum corneum greatly enhance the penetration of topical agents. When used in conjunction with biologics like PRP, growth factor serums, or exosome-rich preparations, microneedling facilitates their delivery into deeper skin layers where they can exert maximal effect. In summary, these therapies share a common theme of tissue remodeling: whether through stem cell differentiation, secreted exosomes and growth factors, platelet-derived signals, or micro-injury, they converge on activating dermal fibroblasts, inducing new collagen formation, and restoring a more youthful extracellular matrix structure.²³

Clinical applications

Regenerative approaches are increasingly applied to a broad range of aesthetic concerns, with encouraging clinical findings. Facial skin rejuvenation is a primary

target: treatments like PRP injections, stem cell grafting, and topical growth factor/exosome products have shown the ability to improve skin tone, elasticity, and reduce rhytides (wrinkles). A recent systematic review and case series of platelet concentrates reported significant enhancements in skin elasticity, texture, and overall facial appearance with minimal adverse effects.²⁴ Patients generally notice smoother, firmer skin and better hydration after a series of such treatments. Notably, regenerative therapies tend to produce gradual, natural-appearing improvements rather than the drastic changes of surgical facelifts, aligning with patient preferences for subtle rejuvenation.

One illustrative example is the use of nanofat grafting (a fat transfer enriched with adipose-derived stem cells) combined with PRP for facial rejuvenation. In a clinical trial by Menkes *et al.* 50 patients received subcutaneous injections of about 18 mL of nanofat mixed with PRP; within 2–4 weeks all patients observed better skin quality and a mild “lifting” effect, and these results persisted at least 6 months. Follow-up biopsies confirmed increased dermal cellularity, vascularity, and collagen/elastin fiber density in treated skin. Such outcomes underscore how stem cell-rich fat combined with growth factors can rejuvenate skin by actually rebuilding tissue structure. Similarly, combining autologous fat or stromal vascular fraction (SVF) cells with PRP has yielded significant improvement in difficult-to-treat atrophic acne scars, with reports of better skin smoothness, reduced pore size, and increased dermal thickness months after treatment (along with high patient satisfaction).²⁵ These findings highlight the potential for scar revision using regenerative methods. In practice, PRP is often used as an adjunct to microneedling or laser resurfacing for acne scars, where it accelerates healing and amplifies collagen deposition in the scar remodeling phase. Mesenchymal stem cells have likewise been applied to recalcitrant chronic wounds and scar therapy, with evidence of reduced fibrosis and improved tissue quality. For instance, platelet-rich plasma and MSC therapies have demonstrated

accelerated wound closure and decreased scar formation by enhancing organized collagen regeneration in the dermis.²⁶

Another major application is hair restoration. Autologous PRP scalp injections have emerged as a popular therapy for androgenetic alopecia (pattern hair loss) in both men and women. Multiple clinical studies and meta-analyses confirm that PRP can significantly increase hair density and hair thickness with minimal side effects. In one systematic review of 10 randomized trials, PRP treatment led to statistically significant improvements in hair count and hair shaft caliber compared to placebo, without any serious adverse events.²⁷ PRP appears to prolong the anagen (growth) phase of hair follicles and improve follicle vascularization via its growth factors, resulting in visibly thicker, fuller hair over several months. It has even shown efficacy in alopecia areata, outperforming steroid injections in one trial in terms of hair regrowth and reduction of inflammatory signs (PRP-treated areas had higher Ki-67+ follicle counts, indicating active proliferation).²² Beyond PRP, researchers are investigating stem cell-derived treatments for hair loss, such as injecting scalp with dermal papilla cells or MSC-derived exosomes. Early case series suggest that exosome injections can stimulate hair regrowth in androgenetic alopecia, potentially by delivering miRNAs and growth factors that activate follicular stem cells. However, these cell-free therapies for hair are still experimental, and more controlled trials are needed.

Overall, regenerative medicine is making inroads in aesthetic dermatology across diverse indications: from improving photoaged facial skin and neck/chest rejuvenation, to treating hyperpigmentation (some reports indicate PRP can help melasma or post-inflammatory hyperpigmentation by promoting dermal repair), reducing stretch marks and cellulite (through collagen remodeling), enhancing fat graft survival in cosmetic body contouring, and even adjunctive use in cosmetic surgery (to accelerate healing and improve scar quality after procedures). Furthermore, there is

growing interest in using these therapies for non-cosmetic dermatologic conditions with aesthetic implications, for example, using MSCs in vitiligo or PRP in chronic ulcers, blurring the line between purely aesthetic and medical dermatology. While many of these applications are in early stages, the accumulating clinical evidence points to regenerative therapies being generally safe, well-tolerated, and capable of delivering noticeable improvements in skin and hair parameters. Crucially, most treatments utilize the patient's own cells or blood components, minimizing the risk of immune rejection and systemic side effects. This autologous nature is a key advantage that contributes to the favorable safety profile observed (e.g. mild transient swelling or bruising is common, but serious complications are rare).

Delivery modalities

Effective delivery of regenerative agents to target tissues is critical for optimal outcomes, and several modalities are employed in aesthetic practice. Direct injection is the most straightforward approach: PRP is typically injected intradermally or subdermally in a grid or mesotherapy pattern across the treatment area (for example, the face or scalp), ensuring an even distribution of growth factors. Stem cells, such as adipose-derived cells or SVF, can be injected alone or within a fat graft to not only deliver cells but also provide some volume fill. In the case of bone marrow or lab-cultured stem cells, these are often delivered via needle into dermal or subcutaneous planes of scars or skin wrinkles. The injection technique (needle versus cannula, depth of placement, etc.) may vary depending on the indication; fine lines are often treated more superficially, whereas deeper injections are used for acne scars or fat graft placement.

Microneedling is a valuable minimally invasive delivery method that complements injections. By creating thousands of micro-channels in the skin, microneedling greatly enhances transdermal absorption of topical formulations. After performing microneedling on the face, practitioners commonly

apply PRP liquid, recombinant growth factor serums, or exosome-rich fluids onto the skin; the open micro-channels allow these large molecules to penetrate into the dermis rather than being blocked by the epidermal barrier. Studies have shown that microneedling combined with topical PRP or growth factors leads to superior skin rejuvenation outcomes compared to topical treatment alone, owing to this improved uptake as well as the synergistic wound-healing stimulus of needling itself. In one review, microneedle-assisted delivery was noted to facilitate the penetration of agents like vitamin C, hyaluronic acid, peptides, and PRP, thereby amplifying collagen induction and clinical effectiveness.²³ Microneedling devices range from simple rollers and pens used in clinics to newer dissolvable microneedle patches that patients can apply at home for gradual delivery of peptides and growth factors, an emerging technology in cosmetic product design.

Another delivery approach is laser or energy-assisted: fractional laser resurfacing not only induces collagen remodeling on its own, but the laser-created microthermal zones can serve a similar role to microneedling channels, allowing topical regenerative products to seep into the skin. Some protocols now combine fractional laser treatment immediately followed by topical PRP or stem cell serum application, with preliminary studies suggesting enhanced rejuvenation effects versus laser alone.

Autologous fat grafting merits mention as both a cosmetic filler and a regenerative delivery system. When processed into nanofat or microfat, the graft contains a high density of regenerative cells that are introduced into the tissue along with the fat matrix. The injected fat acts as a scaffold releasing stem cells and growth factors gradually. For example, in the nanofat-PRP technique described earlier, the cannula-based delivery evenly distributes ADSCs and platelets throughout the subcutaneous plane of the face, marrying volume restoration with biochemical rejuvenation. Fat grafting thus exemplifies a biological delivery vehicle, where the patient's own tissue is

repurposed to convey regenerative potency to areas of volume loss or skin damage. As techniques improve (e.g. using finer cannulas for superficial placement, or additives like PRP to boost graft “take”), the reliability of fat as a cell delivery method is increasing.

Importantly, all these modalities can be combined or layered for greater effect. For instance, a common “vampire facial” procedure entails first performing microneedling over the face, then immediately applying and needling in PRP, effectively combining injection and percutaneous delivery. Similarly, some protocols for hair loss use both dermaroller (microneedling) on the scalp and injection of PRP in the same session to maximize follicle stimulation. The ability to tailor the delivery, whether by needles, cannulas, or topical application, allows clinicians to customize treatment to the patient’s needs and tolerance. Regardless of method, maintaining sterility and cell viability during preparation and delivery is crucial. For example, PRP must be prepared in sterile tubes and usually used within minutes of activation, and cell therapies should be handled gently to preserve live cell function. As the field advances, we are also seeing development of hydrogel and scaffold systems that can be implanted to slowly release growth factors or exosomes at a target site, potentially offering a future alternative to repeated injections.

Limitations

Despite the exciting promise of regenerative aesthetic medicine, there are noteworthy limitations and challenges. One major issue is the heterogeneity of treatment protocols and outcomes in the current literature. Different providers use varying centrifugation techniques for PRP, different dosing and frequency schedules, and there is no universal standard for what constitutes an optimal PRP preparation or stem cell dose. In fact, even basic terminology lacks consistency; for example, PRP preparations may be classified as “PRF,” “CGF,” etc., with subtle processing differences, and there is no consensus on the ideal mode of delivery or activation for aesthetic

indications. This lack of standardization makes it difficult to compare studies and has impeded regulatory approval of off-the-shelf products. The field would benefit from agreed-upon protocols (e.g. minimum platelet count for PRP, or defined phenotyping of cell preparations) to ensure reproducible results across clinics.²²

The current evidence base, while growing, still leans on small trials and anecdotal reports. Many of the published clinical studies involve relatively few patients, short follow-up durations, or lack control groups. Rigorous large-scale randomized controlled trials are still limited for these interventions, which means that certain claims of efficacy (especially for newer approaches like exosomes) should be viewed with caution. Long-term safety data are also sparse; most studies report on outcomes up to 6 or 12 months, so the durability of results beyond a year or two is not well established. There is a need for extended follow-ups to see how long regenerative treatments truly last and whether repeated maintenance sessions are required (as is likely). Encouragingly, what data exist suggest improvements can persist for many months, but the optimal maintenance interval (e.g. annual PRP boosters) is still an open question.

From a safety perspective, autologous therapies like PRP and fat grafting have a strong safety profile, with no risk of immunogenic reaction and very low infection risk when done properly. Nonetheless, when cultured cells or cell-derived products are used, there are theoretical risks of contamination or unwanted growth. For instance, if mesenchymal stem cells are expanded improperly, there is a concern (purely theoretical so far in aesthetics) that they could undergo malignant transformation or promote tumorigenesis. Hence, strict cell handling protocols are essential. A recent discussion highlighted that accumulating DNA mutations in stem cells could pose a cancer risk over time, underscoring the importance of genomic stability in cell therapies.²⁶ Moreover, induced pluripotent stem cells (iPSCs), while potent, come with ethical and safety constraints (including risk of teratoma

formation), so their use in humans is heavily regulated or prohibited in many jurisdictions. In practice, most aesthetic uses stick to minimally manipulated autologous tissues (which regulatory bodies like the FDA consider safe under existing frameworks), but any move toward lab-expanded cells or exosome products will require thorough safety validation.

The regulatory landscape is indeed a limitation in itself. Currently, there are no FDA-approved exosome products for cosmetic use, and authorities have issued warnings about unregulated exosome facials being marketed directly to consumers. This lack of oversight raises concerns about product purity and patient safety; if exosomes are not properly purified, they could contain unwanted cell debris or pathogens. The direct-to-consumer availability of some of these therapies (via medspas, etc.) has outpaced the science; experts caution that patients may be at risk if clinics use unstandardized or non-sterile preparations.²⁸ Strengthening regulatory guidelines and requiring product characterization (for example, mandating that exosome preparations demonstrate certain size ranges and surface markers, and are free of DNA/ protein contaminants) will be important as the field matures. Likewise, professional societies are beginning to issue best-practice recommendations to curb the more dubious or premature uses.

Another limitation is patient-to-patient variability. Outcomes with regenerative treatments can be inconsistent; some patients respond extremely well (the so-called super-responders), while others see only modest changes. This variability can stem from individual differences in biology (e.g. a patient's platelet function or stem cell yield), as well as technical factors (how the PRP was prepared, etc.). More research is needed to identify predictors of response; for example, ongoing studies are examining whether certain blood biomarkers or genetic factors correlate with better collagen regeneration from PRP. Until those are clarified, managing patient expectations is crucial: not everyone will achieve dramatic results,

and often multiple treatment sessions are needed to reach a noticeable improvement.

Cost and accessibility remain practical limitations. These treatments can be expensive; a single PRP facial injection or microneedling with exosomes can cost hundreds to thousands of dollars, and insurance typically does not cover elective aesthetic procedures. Stem cell therapies, which may involve liposuction to harvest fat and laboratory processing, are even more costly. Such financial barriers limit the widespread adoption of regenerative aesthetics at present. Additionally, the need for specialized equipment (centrifuges, cell processing facilities) and trained personnel means these services are concentrated in certain clinics. However, as technologies advance and competition increases, we may see costs come down. Already, PRP kit costs have decreased compared to a decade ago, and simpler office processing for nanofat has been developed. Nonetheless, at this juncture, price is a non-trivial factor that may hinder some patients from pursuing these treatments.²⁶

Finally, a holistic challenge is the gap in knowledge. While we understand the general principles, many questions remain open. How do we best quantify outcomes (since traditional histology or biopsy may not capture functional skin improvements)? What is the optimal combination or sequence of therapies (e.g. should PRP be combined with laser, or stem cells with PRP, for synergy, and in what order)? And critically, what are the limits of these therapies; for instance, can they truly replace a surgical facelift for skin laxity, or are they best used as adjuncts for early aging changes? Current consensus leans toward the latter: regenerative treatments are superb for improving skin quality and minor to moderate aging changes, but are not a substitute for surgical lifting when there is extensive lax skin or musculature involvement. Recognizing these limitations ensures they are used appropriately. In summary, while regenerative aesthetic medicine is safe and innovative, it is not a magic wand. Patient selection, realistic expectations, and combination with

established treatments (when needed) are key to success.

Discussion

The advent of regenerative strategies in aesthetic medicine represents a paradigm shift from simply camouflaging aging signs to biologically reversing or slowing aging process. The benefits of approaches like PRP, stem cell therapy and exosomes are manifold. First, they are generally less invasive than traditional surgical or ablative procedures, resulting in minimal downtime and lower risk profiles. Patients appreciate that treatments such as PRP facials or fat grafting can be done in-office with local anesthesia and yield subtle, natural improvements rather than abrupt changes. Additionally, because more therapies utilize autologous material, the incidence of allergic reactions or severe side effects is exceedingly low, which gives them a safety advantage over synthetic dermal fillers or implant materials. Another benefit is the dual cosmetic and functional gains observed; beyond aesthetic improvement (smoother skin or fuller hair), regenerative treatments often improve the overall health and quality of the tissue. For example, patients treated with PRP for skin rejuvenation frequently report that their skin feels firmer and healthier, not just looks better. Such holistic improvements align with the modern cosmetic trend toward skin quality enhancement and wellness. Furthermore, regenerative treatments can be combined with each other and with conventional therapies to enhance outcomes. The concept of “stacking” treatments, e.g. performing a laser resurfacing and immediately following with PRP to speed healing and boost collagen, is gaining traction, and early studies suggest combination regimens can outperform single-modality treatments. This opens the door to personalized therapy plans where a patient’s regimen is tailored based on their specific skin condition and aging pattern.

Despite these promising advantages, the discussion would be incomplete without addressing the uncertainties and risks. One important consideration is

that results can be variable and often subtle. A critical evaluation of clinical trials indicates that, while on average patients see improvement, not everyone achieves a dramatic change. For example, not all hair loss patients respond robustly to PRP; some may require adjuncts like minoxidil or additional sessions. There is also the risk of over-promising results: the marketing surrounding “stem cell facials” or “exosome therapy” in some medspa settings has arguably gotten ahead of the evidence, which could lead to patient disappointment or mistrust. Practitioners must take care to educate patients that these therapies stimulate natural healing, and thus the improvements occur gradually over weeks to months (in contrast to the instant effect of a filler or toxin injection). Moreover, subtle tissue regeneration cannot accomplish what surgery does in terms of lifting or removing excess skin, so setting realistic goals is paramount.

From a safety standpoint, while major complications are rare, they are not nonexistent. Infection is a minimal risk with any injection-based procedure: rigorous aseptic technique is needed, especially when introducing PRP or cells, to avoid bacterial contamination. There have been isolated reports of granuloma formation or nodules in cases where stem-cell enriched fat was injected (potentially due to immune reaction to impurities or overcorrection), underscoring that even natural therapies can cause adverse reactions if not carefully handled. Another theoretical risk is systemic effect: since these treatments release growth factors, one might question if there is any risk of promoting latent malignancies or unintended tissue growth. To date, no link between PRP or autologous MSC therapy and cancer has been found, and in fact some data suggest PRP may improve tissue health in radiated skin. Nonetheless, cautious monitoring is advised in patients with a history of cancer; many protocols recommend against injecting PRP or growth factors directly into areas with active malignancy. Ethical considerations also come into play, especially as the industry pushes boundaries. The use of embryonic stem cells is ethically charged and largely avoided in cosmetics, and even the banking of

one's own stem cells for future cosmetic use raises questions about equitable access and commercialization of human tissue. Ensuring informed consent is comprehensive is vital: patients should be made aware that some regenerative treatments are newer and not yet fully standardized, and they should consent to the experimental nature if applicable.

A significant gap in current practice is the paucity of long-term and comparative data. We still do not know the optimal number of PRP sessions for sustaining results, or how outcomes from stem cell therapy compare head-to-head with, say, fractional laser resurfacing or retinoid therapy. There is a need for head-to-head trials (for example, PRP vs. fractional laser for acne scars, or exosome serum vs. placebo for wrinkles) to clearly delineate the added value of these novel therapies. Filling these knowledge gaps will help position regenerative treatments appropriately in the aesthetic toolbox. It's also worth noting that training and expertise are crucial. Not all practitioners are equally skilled in preparing and administering these biologics. The field would benefit from standardized training programs and perhaps certification in regenerative aesthetics to ensure practitioners understand the science and the proper techniques (e.g., the importance of gentle handling of fat grafts to keep cells viable, or the correct centrifugation parameters for PRP).

Despite the challenges, the overall trajectory of regenerative aesthetic medicine is one of growth and refinement. Patient satisfaction tends to be high when realistic outcomes are achieved. Many patients prefer the idea of improving themselves "from within" rather than relying on artificial enhancements. In the coming years, we can expect to see more robust protocols and combination treatments that maximize regenerative potential while minimizing risks. The integration of adjunct technologies, for example, using gene expression profiling or AI-based skin analysis to personalize treatment plans, is on the horizon and may address some variability issues. In essence, we are transitioning into an era of biologically active

aesthetics, where interventions are not just cosmetic cover-ups but stimulators of the body's own regenerative capacity. As research continues to close gaps in understanding, and as oversight ensures the quality of therapies, the benefits of these treatments are likely to increasingly outweigh the drawbacks. Close collaboration between dermatologists, plastic surgeons, researchers, and regulatory bodies will be needed to fully unlock the potential of regenerative aesthetics while safeguarding patients.

Conclusion

Regenerative aesthetic medicine has moved from a fringe concept to a central focus of modern cosmetic dermatology and surgery. In conclusion, the current evidence, while still evolving, supports the view that therapies like stem cell injections, PRP, growth factor serums and exosomes can meaningfully rejuvenate skin and hair by engaging the body's natural repair pathways. These treatments offer a paradigm of minimal invasiveness with maximal biochemical effect, aligning with patient desires for safer, more natural anti-aging options. Looking to the future, continued advancements are expected to enhance both efficacy and safety. Standardization of treatment protocols will likely improve consistency of results and ongoing clinical trials will clarify optimal dosing and combinations. It is foreseeable that in the next 5-10 years, we will have bioengineered off-the-shelf products (such as refined exosome preparations and growth factor cocktails) that are approved and widely available, making regenerative treatments more accessible and beyond specialist clinics. Additionally, the convergence of regenerative medicine with technologies like AI and personalized medicine could yield tailored treatments regimens. For example, algorithms might predict which patients will respond best to PRP vs. needling added stem cell therapy, allowing customization for higher success rates.

Crucially, the future of this field will also involve robust oversight and education. As the regulatory environment firms up, patients will have greater

assurance of the quality of the biologics being used, and practitioners will adhere to evidence-based guidelines for their application. We anticipate professional societies will continue to develop training and credentialing in regenerative aesthetics ensuring that providers have the necessary expertise. In terms of clinical practice, regenerative therapies are expected to increasingly complement, rather than outright replace, traditional treatments. For instance, surgical procedures may be combined with peri-operative PRP or stem cell treatments to enhance healing and outcomes, and lasers or chemical peels might be paired with biologic therapies to extend their benefits. This integrated approach can maximize results, improving not only the appearance but also the health issues.

In summary, regenerative medicine is ushering a new era in aesthetic care, one characterized by proactive tissue restoration instead of passive camouflage. Patients are likely to experience more natural and enduring improvements, as we shift focus to rebuilding collagen, revitalizing aged cells and restoring youthful function to aging skin. While challenges regarding evidence quality, safety monitoring and cost need to be addressed, the trajectory is clearly positive. Continued research and clinical experience will refine these treatments, driving them from innovative trials to mainstream practice. The outlook is that within the next decade, a typical anti-aging treatment plan may routinely include a regenerative component, be it PRP infusion, a stem cell boost, or topical exosome therapy as an essential pillar alongside skincare and energy-based devices. This fusion of biology with aesthetics holds great promise for achieving long-held goal of our field; to not only make patients look better, but to make their skin and hair actually younger on a cellular and molecular level. By embracing these advancements responsibly, clinicians can offer outcomes that are superior, sustainable and aligned with the body's own regenerative wisdom, marking a significant leap forward in aesthetic medicine.

Financial support and sponsorship None.

Conflict of interest The authors affirm no conflicts of interest to disclose.

References

1. Zhang S, Duan E. Fighting against Skin Aging: The Way from Bench to Bedside. *Cell Transplant*. 2018;**27**(5):729-38. doi:10.1177/0963689717725755.
2. Surowiecka A, Strużyna J. Adipose-Derived Stem Cells for Facial Rejuvenation. *J Pers Med*. 2022;**12**(1):117. doi:10.3390/jpm12010117.
3. Chen S, He Z, Xu J. Application of adipose-derived stem cells in photoaging: basic science and literature review. *Stem Cell Res Ther*. 2020;**11**(1):491. doi:10.1186/s13287-020-01994-z.
4. Wu DC, Fitzpatrick RE, Goldman MP. A prospective, randomized, double-blind, split-face clinical trial comparing two topical human growth-factor formulations for facial rejuvenation. *J Clin Aesthet Dermatol*. 2017;**10**(5):31–5.
5. Cruciani M, Masiello F, Pati I, Pupella S, De Angelis V. Platelet rich plasma use for treatment of acne scars: an overview of systematic reviews. *Blood Transfus*. 2024;**22**(3):226-38. doi:10.2450/BloodTransfus.536.
6. Wyles SP, Yu GT, Gold M, Behfar A. Topical Platelet Exosomes Reduce Senescence Signaling in Human Skin: An Exploratory Prospective Trial. *Dermatol Surg*. 2024;**50**(11S):S160-S165. doi:10.1097/DSS.0000000000004426.
7. U.S. FDA. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes (2020).
8. U.S. FDA. Regulatory Considerations for HCT/PS: Minimal Manipulation & Homologous Use (Guidance, 2020).
9. Bai G, Thu Minh Truong, Gaurav N Pathak, Babar Rao *et al*. Clinical applications of exosomes in cosmetic dermatology. *Dermatol Ther (Heidelb)*. 2024;14:- (review).
10. Krutmann J, Schikowski T, Morita A, Berneburg M. Environmentally-Induced (Extrinsic) Skin Aging: Exposomal Factors and Underlying Mechanisms. *J Invest Dermatol*. 2021;**141**(4S):1096–1103. doi:10.1016/j.jid.2020.12.011.
11. Farage MA, Miller KW, Elsner P, Maibach HI. Intrinsic and extrinsic factors in skin ageing: a review. *Int J Cosmet Sci*. 2008;**30**(2):87–95. doi:10.1111/j.1468-2494.2007.00415.x.
12. Feng C, Chen X, Yin X, Jiang Y, Zhao C. Matrix Metalloproteinases on Skin Photoaging. *J Cosmet Dermatol*. 2024;**23**(12):3847-62.

13. Quan T, Little E, Quan H. Elevated matrix metalloproteinases and collagen fragmentation in photodamaged human skin. *J Invest Dermatol*. 2013;**133**(5):1362–6. doi:10.1038/jid.2012.509.
14. Zhang S, Duan E. Fighting against Skin Aging: The Way from Bench to Bedside. *Cell Transplant*. 2018;**27**(5):729–38. doi:10.1177/0963689717725755. (Context on conventional vs regenerative strategies.)
15. Schneider I, Calcagni M, Buschmann J. Adipose-derived stem cells applied in skin diseases, wound healing and skin defects: a review. *Cytotherapy*. 2023;**25**(2):105–19.
16. Chen S, He Z, Xu J. Application of ADSCs in photoaging. *Stem Cell Res Ther*. 2020;**11**(1):491.
17. Dal'Forno-Dini T, Birck MS, Rocha M, Bagatin E. Exploring the reality of exosomes in dermatology. *An Bras Dermatol*. 2025;**100**(1):121–30. doi:10.1016/j.abd.2024.09.002.
18. Topical EGF split-face randomized, double-blind (melasma/aging endpoints). *J Drugs Dermatol*. 2018;**17**(6):970–73.
19. Ash M, Meira Zibitt, Orr Shaully, *et al*. The Innovative and Evolving Landscape of Topical Exosome and Peptide Therapy. *ASJ Open Forum*. 2024;ojae017.
20. Wang CK, Tsai TH, Lee CH. Regulation of exosomes as biologic medicines: Regulatory challenges faced in exosome development and manufacturing processes. *Clin Transl Sci*. 2024;**17**(8):e13904. doi:10.1111/cts.13904.
21. Haykal D, Flament F, Shadev M, *et al*. Advances in Longevity: The Intersection of Regenerative Medicine and Cosmetic Dermatology. *J Cosmet Dermatol*. 2025;**24**(7):e70356.
22. Trovato F, Ceccarelli S, Michelini S, *et al*. Advancements in Regenerative Medicine for Aesthetic Dermatology: A Comprehensive Review and Future Trends. *Cosmetics (Basel)*. 2024;**11**(2):49.
23. Hamed R, Abu Nahia BJ, Alkilani AZ, *et al*. Recent Advances in Microneedling-Assisted Cosmetic Applications. *Cosmetics (Basel)*. 2024;**11**(2):51.
24. Malcangi G, Inchingolo AM, Inchingolo AD, *et al*. The Role of Platelet Concentrates and Growth Factors in Facial Rejuvenation: A Systematic Review with Case Series. *Medicina (Kaunas)*. 2025;**61**(1):84.
25. Menkes S, Luca M, Soldati G, Polla L. Subcutaneous injections of nanofat adipose-derived stem cell grafting in facial rejuvenation. *Plast Reconstr Surg Glob Open*. 2020;**8**(1):e2550.
26. Berardesca E, Cameli N. Perspectives of Regenerative Medicine in Dermatology and Cosmetology. *Cosmetics (Basel)*. 2024;**11**(6):188.
27. Evans AG, Mwangi JM, Pope RW, *et al*. Platelet-rich plasma as a therapy for androgenic alopecia: a systematic review and meta-analysis. *J Dermatolog Treat*. 2022;**33**(1):498–511.
28. Vyas KS, Kaufman J, Munavalli GS, Robertson K, Behfar A, Wyles SP. Exosomes: the latest in regenerative aesthetics. *Regen Med*. 2023;**18**(2):181–94.